Q-linea AB (publ)
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, includin… Read more
Q-linea AB (publ) (3F80) - Net Assets
Latest net assets as of June 2025: €129.45 Million EUR
Based on the latest financial reports, Q-linea AB (publ) (3F80) has net assets worth €129.45 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€201.00 Million) and total liabilities (€71.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €129.45 Million |
| % of Total Assets | 64.4% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 53.7 |
Q-linea AB (publ) - Net Assets Trend (2021–2024)
This chart illustrates how Q-linea AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Q-linea AB (publ) (2021–2024)
The table below shows the annual net assets of Q-linea AB (publ) from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-27.46 Million | -114.48% |
| 2023-12-31 | €189.63 Million | +16.21% |
| 2022-12-31 | €163.19 Million | -62.09% |
| 2021-12-31 | €430.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Q-linea AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71255100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.49 Billion | % |
| Total Equity | €-27.46 Million | 100.00% |
Q-linea AB (publ) Competitors by Market Cap
The table below lists competitors of Q-linea AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NETSCIENTIFIC PLC LS-05
F:NTK1
|
$9.23 Million |
|
Kutahya Seker Fabrikasi AS
IS:KTSKR
|
$9.23 Million |
|
UNITED URBAN INV. CORP.
F:0S2
|
$9.23 Million |
|
HMCIB No.7 SPECIAL PURPOSE ACQUISITION COMPANY
KQ:477340
|
$9.24 Million |
|
Mistral Gayrimenkul Yatirim Ortakligi AS
IS:MSGYO
|
$9.23 Million |
|
SenSen Networks Limited
PINK:SNNSF
|
$9.23 Million |
|
Shinsegae Cons
KO:034300
|
$9.23 Million |
|
Clean Seas Seafood Limited
PINK:CTUNF
|
$9.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Q-linea AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 189,635,000 to -27,456,000, a change of -217,091,000 (-114.5%).
- Net loss of 216,871,000 reduced equity.
- Other factors decreased equity by 220,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-216.87 Million | -789.89% |
| Other Changes | €-220.00K | -0.8% |
| Total Change | €- | -114.48% |
Book Value vs Market Value Analysis
This analysis compares Q-linea AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2085.08 | €2.00 | x |
| 2022-12-31 | €790.48 | €2.00 | x |
| 2023-12-31 | €229.64 | €2.00 | x |
| 2024-12-31 | €-33.25 | €2.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Q-linea AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9181.67%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-84.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -53.77% | -2479.22% | 0.02x | 1.13x | €-274.48 Million |
| 2022 | -164.65% | -2101.14% | 0.06x | 1.41x | €-285.01 Million |
| 2023 | -120.95% | -5165.90% | 0.02x | 1.22x | €-248.33 Million |
| 2024 | 0.00% | -9181.67% | 0.02x | 0.00x | €-214.13 Million |
Industry Comparison
This section compares Q-linea AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $263,008,215
- Average return on equity (ROE) among peers: -64.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Q-linea AB (publ) (3F80) | €129.45 Million | -53.77% | 0.55x | $9.23 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |